Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21 Chandra Bose PrabaharanAllan Boyao YangMeena Kishore Sakharkar PRECLINICAL STUDIES 02 August 2019 Pages: 909 - 921
Identification of HGF as a novel target of miR-15a/16/195 in gastric cancer Dongying LiuHaiyang ZhangYi Ba PRECLINICAL STUDIES 14 August 2019 Pages: 922 - 933
Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells Arusha ModiMeenakshi SinghGopeshwar Narayan PRECLINICAL STUDIES 20 August 2019 Pages: 934 - 945
Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines Maximilian HochmairBarbara RathGerhard Hamilton PRECLINICAL STUDIES Open access 24 August 2019 Pages: 946 - 955
The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma Xi’an LiGuangdong HouJianlin Yuan PRECLINICAL STUDIES 28 August 2019 Pages: 956 - 966
Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells Katrin MandaTina PräkeltGuido Hildebrandt PRECLINICAL STUDIES 03 September 2019 Pages: 967 - 976
A new series of acetohydroxamates shows in vitro and in vivo anticancer activity against melanoma Gabriela C. SegatCamila G. MoreiraJoão B. Calixto PRECLINICAL STUDIES 06 September 2019 Pages: 977 - 989
Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines Agnieszka WróbelBeata KolesińskaDanuta Drozdowska PRECLINICAL STUDIES Open access 13 September 2019 Pages: 990 - 1002
Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3 Jingjie SunYuping DuJinbo Yang PRECLINICAL STUDIES 14 October 2019 Pages: 1003 - 1011
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells Toshimi HoshikoYasushi KubotaShinya Kimura PRECLINICAL STUDIES 24 October 2019 Pages: 1012 - 1019
7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells Mariana S. SonegoNatália V. SegattoTiago Collares PRECLINICAL STUDIES 06 November 2019 Pages: 1020 - 1030
Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts Jingya HanYan ZhaoJianfang Wang PRECLINICAL STUDIES 23 November 2019 Pages: 1031 - 1043
Matteucinol, isolated from Miconia chamissois, induces apoptosis in human glioblastoma lines via the intrinsic pathway and inhibits angiogenesis and tumor growth in vivo Ana Gabriela SilvaViviane Aline O. SilvaRosy Iara Maciel de Azambuja Ribeiro PRECLINICAL STUDIES 28 November 2019 Pages: 1044 - 1055
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma Shunji TakahashiMotohide UemuraToshiki Tanikawa PHASE I STUDIES Open access 14 August 2019 Pages: 1056 - 1066
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors Markus JoergerAnastasios StathisRoger von Moos PHASE I STUDIES Open access 30 August 2019 Pages: 1067 - 1076
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer Rachel GoodwinDerek JonkerLesley Seymour PHASE I STUDIES 10 September 2019 Pages: 1077 - 1084
Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer Jeroen RoosendaalHilde RosingAram Oganesian PHASE I STUDIES Open access 11 October 2019 Pages: 1085 - 1095
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2) Ruud van der NollAgnes JagerJan H. M. Schellens PHASE I STUDIES 21 October 2019 Pages: 1096 - 1107
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma Anthony WoodSaby GeorgeRoberto Pili PHASE I STUDIES 25 October 2019 Pages: 1108 - 1116
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1) Ruud van der NollAgnes JagerJan H. M. Schellens PHASE I STUDIES 30 October 2019 Pages: 1117 - 1128
Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial Wanqi ZhuHui MeiJinming Yu PHASE I STUDIES 07 November 2019 Pages: 1129 - 1136
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study Sarah LapointeWarren MasonMartin Smoragiewicz PHASE I STUDIES 09 November 2019 Pages: 1137 - 1144
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer Johanna C. BendellHelge G. BischoffMichael Thomas PHASE I STUDIES 09 November 2019 Pages: 1145 - 1155
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors Albiruni R. Abdul RazakWilson H. Miller JrLia Gore PHASE I STUDIES 16 November 2019 Pages: 1156 - 1165
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population Goldy C. GeorgeTito R. MendozaDavid S. Hong PHASE I STUDIES 25 November 2019 Pages: 1166 - 1174
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors Toshihiko DoiNobuaki MatsubaraNoboru Yamamoto PHASE I STUDIES Open access 10 December 2019 Pages: 1175 - 1185
Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients Linlin ZhangLiang ChenHao Yu SHORT REPORT 21 October 2019 Pages: 1186 - 1191
Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report Atsushi MatsunashiDaichi FujimotoKeisuke Tomii SHORT REPORT 05 September 2019 Pages: 1192 - 1195
Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor Anne Ségolène CottereauLéopoldine BricaireFlorence Tenenbaum SHORT REPORT 24 October 2019 Pages: 1196 - 1199
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors Yosuke AndoTakahiro HayashiKazuyoshi Imaizumi SHORT REPORT Open access 10 December 2019 Pages: 1200 - 1206